Tag Archives: FGEN
Analysts Offer Insights on Healthcare Companies: FibroGen (NASDAQ: FGEN) and Phathom Pharmaceuticals (NASDAQ: PHAT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on FibroGen (FGEN – Research Report) and Phathom Pharmaceuticals (PHAT – Research Report). FibroGen (FGEN) Raymond James analyst Danielle Brill maintained a Sell rating on FibroGen
Analysts Offer Insights on Healthcare Companies: FibroGen (NASDAQ: FGEN), BridgeBio Pharma (NASDAQ: BBIO) and Rocket Pharmaceuticals (NASDAQ: RCKT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on FibroGen (FGEN – Research Report), BridgeBio Pharma (BBIO – Research Report) and Rocket Pharmaceuticals (RCKT – Research Report) with bullish sentiments. FibroGen
Mizuho Securities Maintains a Buy Rating on FibroGen (FGEN)
Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN – Research Report) today and set a price target of $72.00. The company’s shares closed last Monday at $45.36. According to TipRanks.com, Yang is a 1-star analyst with
FibroGen (FGEN) Receives a Buy from Mizuho Securities
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on FibroGen (FGEN – Research Report), with a price target of $72.00. The company’s shares closed last Monday at $36.99, close to its 52-week low of
Mizuho Securities Remains a Buy on FibroGen (FGEN)
In a report issued on August 9, Difei Yang from Mizuho Securities maintained a Buy rating on FibroGen (FGEN – Research Report), with a price target of $65. The company’s shares closed on Friday at $46.20. According to TipRanks.com, Yang
The SVP, Finance and CFO of FibroGen is Exercising Options
Today it was reported that the SVP, Finance and CFO of FibroGen (FGEN – Research Report), Pat Controneo, exercised options to buy 7,000 FGEN shares at $2.90 a share, for a total transaction value of $20.3K. Following this transaction Pat
